CJC-1295 Overview

CJC-1295 is a growth hormone releasing hormone (GHRH) analog that stimulates growth hormone secretion from the pituitary. The DAC (Drug Affinity Complex) version extends its half-life to approximately 8 days, providing sustained GH elevation. It works by amplifying the natural GHRH signal.

Ipamorelin Overview

Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to stimulate GH release. Unlike other GHRPs, it does not significantly increase cortisol or prolactin at standard research doses. Its selectivity makes it one of the most studied peptides in the GH secretagogue class.

Head-to-Head Comparison

Feature	CJC-1295	Ipamorelin
Mechanism	GHRH analog	Ghrelin mimetic (GHRP)
Half-Life	~8 days (DAC)	~2 hours
GH Release Pattern	Sustained elevation	Pulsatile release
Cortisol Impact	Minimal	Very minimal
Price (5mg)	$35-55	$30-50
Research Focus	Sustained GH elevation	Selective GH pulses

Key Differences

The fundamental difference is their mechanism: CJC-1295 amplifies the natural GHRH signal (like turning up the volume), while Ipamorelin acts as a ghrelin mimetic to trigger GH pulses (like pressing the play button). CJC-1295 with DAC provides extended GH elevation lasting days, while Ipamorelin produces acute GH spikes lasting hours. Many research protocols combine both peptides for synergistic effects, using CJC-1295 for baseline elevation and Ipamorelin for additional pulsatile release.

Which Should You Choose?

Choose CJC-1295 for research into sustained GH elevation and long-acting GHRH analogs. Choose Ipamorelin for studying selective GH secretagogues with minimal off-target effects. For comprehensive GH axis research, many protocols combine both peptides, as they work through complementary pathways. The combination is one of the most commonly studied pairings in growth hormone research.

Frequently Asked Questions

Can CJC-1295 and Ipamorelin be combined?

Yes, combining CJC-1295 and Ipamorelin is one of the most common research protocols. They work through complementary mechanisms — GHRH amplification and ghrelin mimicry — for synergistic GH release.

Which has fewer side effects in research?

Ipamorelin is generally considered more selective with fewer off-target effects. It does not significantly raise cortisol or prolactin, making it preferred for research requiring clean GH stimulation.